- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06847724
En effektivitets- och säkerhetsstudie med integrerad farmakokinetik (PK) och farmakodynamisk (PD) -bedömning för att jämföra den föreslagna Ocrelizumab Biosimilar CyB704 och OcRevus hos deltagare med återfallande multipel skleros (RMS)
A Randomized, Double-blind, Parallel-group Study to Compare the Pharmacokinetics, Efficacy, Pharmacodynamics, Safety, and Immunogenicity of CYB704 (Proposed Ocrelizumab Biosimilar) and Ocrevus® (EU-authorized and US-licensed) in Participants With Relapsing Multiple Sclerosis (RMS)
The goal of this clinical trial is to learn if drug CYB704, a proposed biosimilar to Ocrevus, works to treat multiple sclerosis in the same way as the reference product Ocrevus(R).
The main questions it aims to answer are:
- Is CYB704 distributed in the body in the same way as the reference product (demonstration of pharmacokinetic (PK) similarity)?
- Does have CYB704 the same treatment effect and side effects as the reference product?
Researchers will compare CYB704 to a Ocrevus (Ocrevus-US and Ocrevus-EU). Participants will:
- Take drug CYB704 or Ocrevus (Ocrevus-US and Ocrevus-EU)
- Visit the clinic for at least 15 treatment visits, checkups and tests
- Will undergo regular magnetic resonance imaging (MRI) examinations
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Banja Luka, Bosnien och Hercegovina
- Sandoz Investigational Site
-
Bihać, Bosnien och Hercegovina
- Sandoz Investigational Site
-
Sarajevo, Bosnien och Hercegovina
- Sandoz Investigational Site
-
Sarajevo, Bosnien och Hercegovina
- Sandoz Investigational Site 2
-
-
-
-
-
Pleven, Bulgarien
- Sandoz Investigational Site
-
Plovdiv, Bulgarien
- Sandoz Investigational Site
-
Plovdiv, Bulgarien
- Sandoz Investigational Site 2
-
Sofia, Bulgarien
- Sandoz Investigational Site 2
-
Sofia, Bulgarien
- Sandoz Investigational Site 3
-
Sofia, Bulgarien
- Sandoz Investigational Site
-
Sofia, Bulgarien
- Sandoz Investigational Site 4
-
Sofia, Bulgarien
- Sandoz Investigational Site 5
-
-
-
-
Florida
-
Maitland, Florida, Förenta staterna, 32751
- Sandoz Investigational Site
-
Ormond Beach, Florida, Förenta staterna, 32174
- Sandoz Investigational Site
-
-
-
-
-
Rustavi, Georgien
- Sandoz Investigational Site
-
Tbilisi, Georgien
- Sandoz Investigational Site
-
Tbilisi, Georgien
- Sandoz Investigational Site 2
-
Tbilisi, Georgien
- Sandoz Investigational Site 3
-
Tbilisi, Georgien
- Sandoz Investigational Site 4
-
Tbilisi, Georgien
- Sandoz Investigational Site 5
-
Tbilisi, Georgien
- Sandoz Investigational Site 6
-
Tbilisi, Georgien
- Sandoz Investigational Site 7
-
Tbilisi, Georgien
- Sandoz Investigational Site 8
-
-
-
-
-
Varaždin, Kroatien
- Sandoz Investigational Site
-
Zagreb, Kroatien
- Sandoz Investigational Site
-
-
-
-
-
Shtip, Nordmakedonien
- Sandoz Investigational Site
-
Skopje, Nordmakedonien
- Sandoz Investigational Site
-
-
-
-
-
Bydgoszcz, Polen
- Sandoz Investigational Site
-
Katowice, Polen
- Sandoz Investigational Site
-
Katowice, Polen
- Sandoz Investigational Site 2
-
Lodz, Polen
- Sandoz Investigational Site
-
Lublin, Polen
- Sandoz Investigational Site
-
Lublin, Polen
- Sandoz Investigational Site 2
-
Nowa Sól, Polen
- Sandoz Investigational Site
-
Poznan, Polen
- Sandoz Investigational Site
-
Poznan, Polen
- Sandoz Investigational Site 2
-
Szczecin, Polen
- Sandoz Investigational Site
-
Warsaw, Polen
- Sandoz Investigational Site
-
Zabrze, Polen
- Sandoz Investigational Site
-
-
-
-
-
Belgrade, Serbien
- Sandoz Investigational Site
-
Niš, Serbien
- Sandoz Investigational Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Diagnosis of RMS (relapsing remitting multiple sclerosis (MS) or active secondary progressive MS)
- Evidence of recent disease activity as defined in study protocol
- Expanded Disability Status scale score of 0 to 5.5 (inclusive) at screening
- Neurological stability (no new signs or symptoms referable to Central Nervous System (CNS) within 30 days before both screening and first study treatment
Exclusion Criteria:
- Diagnosis of primary progressive MS
- Disease duration of more than 10 years in participants with an Expanded Disability Status Scale (EDSS) ≤2.0 at screening
- Inability to complete an MRI or contraindication to gadolinium administration
- History of allergic or anaphylactic reactions to ocrelizumab or one of the premedications (methylprednisolone or equivalent corticosteroid, antihistamine, antipyretic)
- Pregnant participants
- Current or history of medical conditions as outlined in the study protocol
- Prohibited medications (current and history) as outlined in the study protocol
- Abnormal laboratory blood values as outlined in the study protocol
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: CYB704
Drug: CYB704 (Ocrelizumab) Patients will be dosed 300 mg on day 1 and day 15. Subsequent dose of 600 mg will be administered 24 weeks after the initial dose. |
Intravenous Infusion
Andra namn:
|
|
Aktiv komparator: Ocrevus-US/Ocrevus-EU
Drug: Ocrevus-US/Ocrevus-EU Patients will be dosed 300 mg on day 1 and day 15 with Ocrevus-US. Subsequent dose of 600 mg Ocrevus-EU will be administered 24 weeks after the initial dose. |
Intravenous Infusion
Andra namn:
Intravenous Infusion
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Area under the concentration time curve
Tidsram: Week 1 - 3, week 3 - 25
|
Demonstrate similar PK between Ocrevus and CYB704 |
Week 1 - 3, week 3 - 25
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Area under the plasma concentration versus time curve (AUC)
Tidsram: Week 1 - 25
|
Compare PK between Ocrevus and CYB704 |
Week 1 - 25
|
|
Peak Plasma Concentration (Cmax)
Tidsram: Day 1 and Day 15
|
Demonstrate similar PK between Ocrevus and CYB704 |
Day 1 and Day 15
|
|
CD19+ B-cell count
Tidsram: Up to 48 weeks
|
Compare PD between Ocrevus and CYB704 |
Up to 48 weeks
|
|
Number of new T1 GdE lesions on brain MRI scans
Tidsram: Up to 48 weeks
|
Compare efficacy between Ocrevus and CYB704 |
Up to 48 weeks
|
|
Number of T1 GdE lesions
Tidsram: Up to 48 weeks
|
Compare efficacy between Ocrevus and CYB704 |
Up to 48 weeks
|
|
Number of new/enlarging T2 lesions
Tidsram: Up to 48 weeks
|
Compare efficacy between Ocrevus and CYB704 |
Up to 48 weeks
|
|
Number of combined unique active lesions
Tidsram: Up to 48 weeks
|
Compare efficacy between Ocrevus and CYB704 |
Up to 48 weeks
|
|
Annualized Relapse Rate
Tidsram: Up to 48 weeks
|
Compare efficacy between Ocrevus and CYB704 |
Up to 48 weeks
|
|
Treatment emergent Adverse Events and Serious Adverse Events
Tidsram: Up to 48 weeks
|
Compare safety between Ocrevus and CYB704 |
Up to 48 weeks
|
|
Rate of patients with anti-drug antibodies
Tidsram: Up to 48 weeks
|
Compare immunogenicity between Ocrevus and CYB704 |
Up to 48 weeks
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CCYB704A12301
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .